Elotuzumab: no additional effect in patients with newly diagnosed multiple myeloma

Prognosis in patients with multiple myeloma has markedly improved with the emergence of novel therapies (ie, proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and autologous haematopoietic stem-cell transplantation [HSCT]). For transplant-eligible patients, triplet induction chemotherapy with lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous HSCT and subsequent lenalidomide maintenance is the standard treatment, with reported median overall survival time of approximately 10 years.